Trials / Completed
CompletedNCT01910012
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Polaris Group · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-PEG 20 |
Timeline
- Start date
- 2015-01-06
- Primary completion
- 2016-09-12
- Completion
- 2017-05-05
- First posted
- 2013-07-29
- Last updated
- 2020-10-01
Locations
6 sites across 2 countries: United States, Taiwan
Source: ClinicalTrials.gov record NCT01910012. Inclusion in this directory is not an endorsement.